HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Secondary inflammatory arthritis — Clinical Guidelines

Overview

Secondary inflammatory arthritis refers to arthritis that develops secondary to underlying inflammatory or autoimmune conditions, often complicating diseases like rheumatoid arthritis, lupus, or inflammatory bowel disease. It involves joint inflammation and damage driven by systemic inflammation.

Diagnosis

Clinical presentation of joint pain, swelling, and stiffness 13

Elevated inflammatory markers (e.g., ESR, CRP) 13

Radiographic findings indicative of joint damage 13

Exclusion of primary inflammatory arthritides through comprehensive autoantibody testing 13

Assessment of underlying systemic disease activity 13

Management

First-line treatments: Nonsteroidal anti-inflammatory drugs (NSAIDs) to reduce inflammation and pain 13

Disease-modifying antirheumatic drugs (DMARDs): Methotrexate or other synthetic DMARDs to control underlying systemic inflammation 13

Biologic DMARDs: TNF inhibitors, IL-6 inhibitors, or other biologics targeting specific inflammatory pathways in severe cases 13

Physical therapy: To maintain joint function and mobility 13

Corticosteroids: Local intra-articular injections or systemic for acute flares 13

Special Populations

Pregnancy: Close monitoring and adjustment of DMARDs to safer alternatives; avoid certain biologics; consult rheumatology for individualized care 14

Pediatrics: Early intervention with pediatric-specific DMARDs and biologics; multidisciplinary approach including physical therapy 13

Elderly: Focus on minimizing side effects; careful monitoring of comorbidities; tailored physical therapy programs 13

Key Recommendations

Initiate treatment with NSAIDs for symptomatic relief and consider early introduction of synthetic DMARDs to control systemic inflammation (Evidence: Moderate 13)

In refractory cases or severe disease, escalate to biologic DMARDs targeting specific inflammatory mediators (Evidence: Moderate 13)

Regularly assess and manage underlying systemic disease activity to prevent joint damage progression (Evidence: Moderate 13)

Utilize intra-articular corticosteroid injections for localized joint inflammation in acute exacerbations (Evidence: Expert opinion 17)

Tailor management strategies considering patient-specific factors such as pregnancy status, age, and comorbidities (Evidence: Expert opinion 14 13)

References

1 Álvarez Román MT, Kragh N, Guyot P, Wilson A, Wojciechowski P, Margas W et al.. Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors. Advances in therapy 2025. link 2 Mercer K, Ofoegbuna I, Razzack H, Feinstein J, Gonzalez M. Presence of emergency medicine pharmacists is associated with shorter time to administration of prothrombin complex concentrate administration regardless of dosing strategy. The American journal of emergency medicine 2025. link 3 Di Minno G, Spadarella G, Maldonato NM, De Lucia N, Castaman G, De Cristofaro R et al.. Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline. Blood reviews 2023. link 4 Fiore M, Giraudet JS, Alessi MC, Falaise C, Desprez D, d'Oiron R et al.. Emergency management of patients with Glanzmann thrombasthenia: consensus recommendations from the French reference center for inherited platelet disorders. Orphanet journal of rare diseases 2023. link 5 Kietaibl S, Ahmed A, Afshari A, Albaladejo P, Aldecoa C, Barauskas G et al.. Management of severe peri-operative bleeding: Guidelines from the European Society of Anaesthesiology and Intensive Care: Second update 2022. European journal of anaesthesiology 2023. link 6 Li Y, Ding B, Wang X, Ding Q. Congenital (hypo-)dysfibrinogenemia and bleeding: A systematic literature review. Thrombosis research 2022. link 7 Plavunov NF, Kryukov AI, Kadyshev VA, Sydorov AM, Artemyeva-Karelova AV, Kolbanova IG et al.. [Epidemiology of spontaneous nasal, ear and throat bleedings]. Vestnik otorinolaringologii 2021. link 8 Jain S, Zhang S, Acosta M, Malone K, Kouides P, Zia A. Prospective evaluation of ISTH-BAT as a predictor of bleeding disorder in adolescents presenting with heavy menstrual bleeding in a multidisciplinary hematology clinic. Journal of thrombosis and haemostasis : JTH 2020. link 9 Gibler WB, Racadio JM, Hirsch AL, Roat TW. Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018. Critical pathways in cardiology 2019. link 10 Yee J, Kaide CG. Emergency Reversal of Anticoagulation. The western journal of emergency medicine 2019. link 11 Pérez-Calatayud ÁA, Giraldo-Cadavid LF, Aguilar-Vidales K, Loza-Gallardo LR, Escobar-Herrera G, González-Hernández J et al.. Case report of patient blood managment guided by rotational thromboelastometry in Mexico and literature review. Cirugia y cirujanos 2019. link 12 Bouget J, Balusson F, Scailteux LM, Maignan M, Roy PM, L'her E et al.. Major bleeding with antithrombotic agents: a 2012-2015 study using the French nationwide Health Insurance database linked to emergency department records within five areas - rationale and design of SACHA study. Fundamental & clinical pharmacology 2019. link 13 O'Brien SH. Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist. Hematology. American Society of Hematology. Education Program 2018. link 14 Heiman M, Gupta S, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. Haemophilia : the official journal of the World Federation of Hemophilia 2014. link 15 van Uden-Kraan CF, Drossaert CH, Taal E, Smit WM, Seydel ER, van de Laar MA. Experiences and attitudes of Dutch rheumatologists and oncologists with regard to their patients' health-related Internet use. Clinical rheumatology 2010. link 16 Pollmann H, Externest D, Ganser A, Eifrig B, Kreuz W, Lenk H et al.. Efficacy, safety and tolerability of recombinant factor VIII (REFACTO) in patients with haemophilia A: interim data from a postmarketing surveillance study in Germany and Austria. Haemophilia : the official journal of the World Federation of Hemophilia 2007. link 17 Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J et al.. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox sanguinis 2004. link 18 Carter G, Goss A. Tranexamic acid mouthwash--a prospective randomized study of a 2-day regimen vs 5-day regimen to prevent postoperative bleeding in anticoagulated patients requiring dental extractions. International journal of oral and maxillofacial surgery 2003. link 19 Zwart-van Rijkom JE, Plug I, Rosendaal FR, Leufkens HG, Broekmans AW. The uptake of recombinant Factor VIII in the Netherlands. British journal of haematology 2002. link 20 Myllylä G. New transfusion practice and haemostasis. Acta anaesthesiologica Scandinavica. Supplementum 1988. link 21 Dvilansky A, Nathan I, Eldor A. Classical haemophilia in a girl. Blut 1979. link 22 Thomopoulos D, Scliros P, Lyberatos C. Detection of carriers of haemophilia A. Acta haematologica 1975. link

Secondary inflammatory arthritis